Off-the-Shelf cell therapy takes on tough lymphoma
NCT ID NCT07248163
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a one-time treatment using universal (off-the-shelf) CAR-T cells that target CD19, a protein on cancer cells. It is for adults with relapsed or refractory B-cell non-Hodgkin lymphoma who have few options left. The main goal is to check safety and find the right dose, with up to 6 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA,B CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghi Tongji Hospital (Tongji Hospital of Tongji University)
RECRUITINGShanghai, 620000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take on tough blood cancers
- Lymphoma Patients' vaccine response under scrutiny
- Muscle loss may predict CAR-T outcomes in lymphoma
- New CAR-T therapy targets Hard-to-Treat lymphoma
- New liquid biopsy could spot hidden brain lymphoma
- New hope for Tough-to-Treat lymphoma: Two-Drug combo enters Mid-Stage trial